1095 related articles for article (PubMed ID: 15122171)
1. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
2. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
3. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
4. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
Rothermel CD
Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
Reechaipichitkul W; Assawasanti K; Chaimanee P
Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
7. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
Brauers J; Ewig S; Kresken M
Pneumologie; 2002 Oct; 56(10):605-9. PubMed ID: 12375222
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens.
Song JH; Jung SI; Ki HK; Shin MH; Ko KS; Son JS; Chang HH; Kim SW; Lee H; Kim YS; Oh WS; Peck KR; Chongthaleong A; Lalitha MK; Perera J; Yee TT; Jamal F; Kamarulzaman A; Carlos CC; So T;
Clin Infect Dis; 2004 Jun; 38(11):1570-8. PubMed ID: 15156445
[TBL] [Abstract][Full Text] [Related]
11. Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
Wiener-Well Y; Raveh D; Schlesinger Y; Yinnon AM; Rudensky B
Chemotherapy; 2009; 55(2):97-104. PubMed ID: 19145079
[TBL] [Abstract][Full Text] [Related]
12. [Antibiotic therapy for community acquired Streptococcus pneumoniae pneumonia: clinical relevance of antibiotic resistance].
Bédos JP; Bruneel F
Med Mal Infect; 2006; 36(11-12):667-79. PubMed ID: 16842956
[TBL] [Abstract][Full Text] [Related]
13. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?
Peterson LR
Clin Infect Dis; 2006 Jan; 42(2):224-33. PubMed ID: 16355333
[TBL] [Abstract][Full Text] [Related]
14. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2005 Dec; 26(6):575-616. PubMed ID: 16388429
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
Lynch III JP; Martinez FJ
Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pneumococcal pneumonia.
Pallares R
Semin Respir Infect; 1999 Sep; 14(3):276-84. PubMed ID: 10501315
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia.
Aspa J; Rajas O; de Castro FR
Expert Opin Pharmacother; 2008 Feb; 9(2):229-41. PubMed ID: 18201146
[TBL] [Abstract][Full Text] [Related]
19. [Penicillin-resistant pneumococci and the empirical use of penicillins in the treatment of community-acquired acute pneumonia].
Sánchez C; Armengol R; Mir I; Lite J; Garau J
Enferm Infecc Microbiol Clin; 1992; 10(6):334-9. PubMed ID: 1391015
[TBL] [Abstract][Full Text] [Related]
20. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
Appelbaum PC
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
